Elucidating the roles of AMPK isoforms in Alzheimer's Disease Pathogenesis
阐明 AMPK 亚型在阿尔茨海默病发病机制中的作用
基本信息
- 批准号:9468906
- 负责人:
- 金额:$ 4.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-30 至 2019-09-29
- 项目状态:已结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmyloid beta-ProteinAmyloid depositionBehaviorBehavioralBiochemicalBrainCause of DeathCell modelCognition DisordersCommunitiesDefectDementiaDevelopmentDiseaseElderlyElectrophysiology (science)EpidemicEventExcisionFunctional disorderGenesGeneticGenetic TranslationGoalsHippocampus (Brain)HomeostasisHumanImpairmentInterventionKnockout MiceLearningLightLong-Term PotentiationMemoryMemory LossMemory impairmentMethodsMolecularMusMutant Strains MiceMutationNeurodegenerative DisordersNeuronsPathogenesisPathologyPatientsPhosphotransferasesPreventionPreventive InterventionProsencephalonProtein BiosynthesisProtein IsoformsProtein KinaseProteinsProto-Oncogene Proteins c-aktPublicationsRegulationRepressionResearchRoleShort-Term MemorySignal PathwaySignal TransductionSynaptic plasticityTechnical ExpertiseTestingTimeTransgenic MiceTreatment EfficacyV717FWorkaging populationbrain healthbrain tissuediagnostic biomarkerexcitatory neuronexperimental studyfamilial Alzheimer diseasehuman tissueimpaired capacityimprovedmorris water mazemouse modelmutant mouse modelnew therapeutic targetnovelnovel diagnosticsobject recognitionrapid growthsensorspatial memorysynaptic failuretargeted biomarkertherapeutic target
项目摘要
Project Summary/Abstract
Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and may become a new
epidemic in the 21st century in accordance with the rapid growth of the aging population. There is currently no
known cure or treatment to stop the progression of AD. Moreover, the basic molecular mechanisms
responsible for AD remain elusive. Two key events in AD pathophysiology are impaired capacity of de novo
protein synthesis (mRNA translation) and disrupted cellular energy homeostasis. AMP-activated protein kinase
(AMPK) acts as a central cellular energy sensor to maintain cellular energy homeostasis. Furthermore AMPK
integrates several signaling pathways (including AKT, GSK3, mTORC1, and eEF2) controlling de novo protein
synthesis, dysregulation of which is implicated in cognitive syndromes associated with neurodegenerative
diseases including AD. Mammalian AMPK is a heterotrimeric protein with a catalytic α subunit and regulatory
β/γ subunit. The α subunit of AMPK exists in two isoforms: α1 and α2, and their roles in AD are unknown. By
investigating brain tissue from post mortem human AD patients and a transgenic mouse model of AD, I have
found that levels of AMPKα1 are dramatically increased while levels of AMPKα2 are decreased. The central
hypothesis of the current project is that disruption of AMPK isoform homeostasis represents a key molecular
mechanism of AD pathophysiology. Thus, the objective of this project is to determine whether selective AMPK
isoform inhibition (and subsequent altering of AMPK isoform homeostasis) alleviates AD-associated deficits in
protein synthesis and memory formation. This project will utilize a novel mouse model in which Prkaa1 and
Prkaa2 (genes that encode AMPK α1 and α2 subunits, respectively) were removed in excitatory neurons in
forebrains and hippocampus late in development, to generate brain- and isoform-specific conditional AMPKα1
and α2 knockout mice (AMPKα1 cKO and AMPKα2 cKO). We have further crossed the heterozygous
AMPKα1/2 cKO mice [AMPKα1(+/-) and AMPKα2(+/-)] with Tg19959 AD mouse model (containing two familial
AD mutations: K670N and V717F) to generate Tg19959/AMPKα1(+/-) and Tg19959/AMPKα2(+/-) double
mutant mice. Using behavioral, electrophysiological, and biochemical methods, the experiments here will 1)
elucidate the effects of genetic repression of AMPK isoforms on AD-associated synaptic plasticity impairments;
2) determine the effects of AMPK isoform suppression in learning and memory deficits in AD model mice; and
3) establish whether specific AMPK isoform reduction improves AD pathology, including brain amyloid
deposition and de novo protein synthesis impairments. The experimental findings derived from this project will
help elucidate a novel mechanism for AD pathophysiology, shedding a light on potentially new diagnostic
biomarkers and therapeutic targets.
项目摘要/摘要
阿尔茨海默病(AD)是老年人中最常见的痴呆形式,并可能成为一种新的
21世纪的疫情符合老龄化人口的快速增长。目前没有
已知的治疗方法或治疗方法可以阻止AD的进展。此外,基本的分子机制
对AD的责任仍然难以捉摸。阿尔茨海默病病理生理学中的两个关键事件是新生能力受损
蛋白质合成(信使核糖核酸翻译)和细胞能量动态平衡被破坏。AMP激活的蛋白激酶
(AMPK)作为一种中枢细胞能量感受器,维持细胞能量稳态。此外,AMPK
整合了多种控制从头蛋白的信号通路(包括AKT、GSK3、mTORC1和eEF2)
合成,其调节失调与神经退行性变相关的认知综合征有关
疾病包括阿尔茨海默病。哺乳动物AMPK是一种具有催化α亚基和调控功能的异源三聚体蛋白
β/γ亚基。AMPK的α亚基以两种亚型存在:α1和α2,它们在AD中的作用尚不清楚。通过
研究死后人类AD患者的脑组织和AD转基因小鼠模型,我有
发现AMPKα1水平显著升高,而AMPKα2水平显著降低。中环
目前项目的假设是,AMPK亚型稳态的破坏代表了一个关键的分子
AD的病理生理学机制。因此,本项目的目标是确定选择性AMPK
异构体抑制(以及随后改变AMPK异构体稳态)减轻AD相关的缺陷
蛋白质的合成和记忆的形成。该项目将利用一种新的小鼠模型,在该模型中,Prkaa1和
在兴奋性神经元中,Prkaa2(分别编码AMPKα1和α2亚单位的基因)被移除
发育后期的前脑和海马体,产生脑和异构体特异的条件性AMPKα1
α2基因敲除小鼠(AMPKα1CKO和AMPKα2CKO)。我们已经进一步跨越了杂合子
采用Tg19959 AD模型的AMPKα1/2 CKO小鼠[AMPKα1(+/-)和AMPKα2(+/-)]
AD突变:K670N和V717F)产生Tg19959/AMPKα1(+/-)和Tg19959/AMPKα2(+/-)双
突变的小鼠。使用行为学、电生理学和生化方法,这里的实验将1)
阐明AMPK亚型基因抑制对AD相关突触可塑性损伤的影响;
2)检测AMPK亚型抑制对AD模型小鼠学习记忆障碍的影响;
3)确定特定的AMPK亚型减少是否改善了AD的病理,包括脑淀粉样蛋白
沉积和从头合成蛋白质的损伤。从这个项目中得出的实验结果将
有助于阐明AD病理生理学的新机制,为潜在的新诊断提供线索
生物标志物和治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Helena Rose Zimmermann其他文献
Helena Rose Zimmermann的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 4.4万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 4.4万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 4.4万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 4.4万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 4.4万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 4.4万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 4.4万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 4.4万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 4.4万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 4.4万 - 项目类别:
Studentship Programs